Stock Taper
SCREENER COMPARE ANY 2 STOCKS
IBRX
IMMUNITYBIO, INC.
NASDAQ
$8.05
▼ DOWN 4.17% (-0.35)

KEY STATISTICS

Market Cap$8.43 B
52w High$12.43
52w Low$1.95
Dividend Yield—
Frequency—
P/E-8.30
Volume7.93M
Shares Out.1.05B

COMPANY

LEADERSHIP

Richard Gerald Adcock
CHIEF EXECUTIVE
Richard Gerald Adcock

COMPENSATION 2026

Salary$831,667
Stock Awards$2,787,828
Incentive Plan Pay$485,166
All Other Comp.$117,202
Total$12,716,953

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 28, 2015
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
688

PRICE TARGET

Target High$12.00
Target Low$12.00
Target Median$12.00
Target Consensus$12.00

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$59.23M
NOV
3
TUE

PRICE

$8.05 ▼ DOWN 4.17% (−$0.35)
$8.00$8.10$8.20$8.309:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM8.05

About ImmunityBio, Inc.

https://immunitybio.com ↗

ImmunityBio, Inc. is a San Diego-based biotech company developing immunotherapies and vaccines for cancers and infectious diseases, with several candidates in advanced clinical trials and collaborations with major research institutions.

INDUSTRY

Biotechnology

A PRODUCT IMMUNITYBIO, INC. IS KNOWN FOR

ANKTIVA® (nogapendekin alfa inbakicept-pmln)
ANKTIVA® (nogapendekin alfa inbakicept-pmln)

ANKTIVA, FDA-approved for BCG-unresponsive non-muscle invasive bladder cancer, is ImmunityBio’s first commercial immunotherapy product, fueling revenue growth and advancing their focus on immune-activating cancer treatments.

COMPETITORS

COMPETITOR
BMY COMPARE
CGON COMPARE
JNJ COMPARE
MRK COMPARE
TARA COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$31.78M $38.27M ▲$44.17M ▲$50.67M ▲
Product and Service Other$281K $13K ▼$39K ▲$568K ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$31.8M $38.27M ▲$44.18M ▲$50.72M ▲
Europe$262K $16K ▼$24K ▲$518K ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
153
LISTED HERE
26
RANKED BY POSITION SIZE
XBI
0.94% · 13.3M
VTI
0.00% · 11.6M
IWM
0.10% · 9.8M
PSC
0.49% · 1.6M
SCHA
0.06% · 1.5M
RVER
3.13% · 609.1K
FNY
0.74% · 524.2K
LABU
0.64% · 483.0K
XRSU.L
0.10% · 346.1K
BUZZ
2.44% · 287.0K
ONEQ
0.02% · 244.5K
HY
HYP
2.74% · 235.0K
BBP
1.45% · 206.2K
RSSL
0.10% · 184.5K
SILX
2.09% · 139.5K
FSCC
0.26% · 111.0K
BBSC
0.12% · 108.4K
CN
CNCR
3.28% · 104.7K
JHMM
0.01% · 100.4K
IBBQ
0.55% · 65.2K
GERM
3.14% · 64.7K
BKMC
0.08% · 62.6K
GSSC
0.03% · 39.5K
BIB
0.30% · 37.4K
STXK
0.13% · 13.7K
RTWP.L
0.04% · 11.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
16.56%
HOLDERS
489
TOP 12 OF 489 · RANKED BY POSITION SIZE
Blackrock, Inc.
34.1M sh · $298.4M
Vanguard Group Inc
32.8M sh · $64.9M
State Street Corp
21.4M sh · $187.34M
Jane Street Group, LLC
14.2M sh · $28.16M
D. E. Shaw & Co., Inc.
12.6M sh · $96.42M
Blackrock Inc.
11.4M sh · $72.19M
Two Sigma Investments, LP
11.1M sh · $97.16M
Geode Capital Management, LLC
9.8M sh · $86.23M
Armistice Capital, LLC
7.8M sh · $20.5M
Heights Capital Management, Inc
6.6M sh · $16.15M
Goldman Sachs Group Inc
6.2M sh · $12.18M
Millennium Management LLC
5.6M sh · $48.85M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Daniel Goldman
Daniel Goldman
Sale (Full)
2023-03-06

INSIDER TRADES

★
DIRECTOR
Selecky Christobel
Sale · 159.5K shares
2026-07-01
★
DIRECTOR
Cohen Cheryl
Sale · 56.0K shares
2026-07-02
★
DIRECTOR
Selecky Christobel
Purchase · 124.4K shares
2026-07-01
★
DIRECTOR
Cohen Cheryl
Purchase · 56.0K shares
2026-07-02

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 1
5 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY BTIG BUY D. Boral Capital BUY Piper Sandler OVERWEIGHT Jefferies BUY

SECTORS PEERS

PEERPRICE
LQDA$67.69COMPARE
COGT$34.67COMPARE
DNLI$24.00COMPARE
RCUS$29.21COMPARE
BEAM$29.32COMPARE
VRDN$23.08COMPARE
AGIO$33.32COMPARE
RXRX$3.34COMPARE